Key facts
- Luminopia’s last known valuation is $44.0M (Jun 2023).
- It has raised $37.8M across 5 recorded rounds; the latest was Early Stage VC ($15.8M) in Jun 2023.
- Notable investors include MassChallenge, Collaborative Fund, Harvard Innovation Launch Lab, Sony Innovation Fund, Bantam Group — 18 tracked in total.
- Luminopia has filed 5 Form Ds with the SEC since 2017, most recently Jun 2023 ($15.8M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Luminopia
Funding rounds
5 roundsAbout Luminopia
Developer of a binocular therapeutic device designed to pioneer a new class of treatments for significant neuro-visual disorders. The company offers treatment for amblyopia, or lazy eye, using binocular vision and is developing a product to treat amblyopia which is the leading cause of vision loss among children, enabling healthcare professionals to treat significant neuro-visual disorders.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 23
- Website
- luminopia.com/
- Ownership
- Privately Held (backing)
Luminopia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luminopia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luminopia in its N-PORT filings yet. We sweep new filings monthly.